# Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis

> **NCT00030381** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 22 (actual)

## Conditions studied

- Primary Systemic Amyloidosis

## Interventions

- **DRUG:** 4'-iodo-4'-deoxydoxorubicin
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00030381
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-12
- **Primary completion:** 2003-01
- **Final completion:** —
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Administratively complete.
- **Last updated:** 2013-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00030381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00030381, "Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00030381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*